Trial Profile
A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Apr 2023
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Docetaxel; Etoposide
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Jul 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
- 05 Jun 2007 Follow-up data have been reported at ASCO 2007.
- 13 Oct 2005 New trial record.